# Study of FVIIa Variant BAY86-6150 (B0189) in Subjects With Moderate or Severe Hemophilia Types A or B With or Without Inhibitors

> **NCT01921855** · PHASE1 · COMPLETED · sponsor: **Bayer** · enrollment: 16 (actual)

## Conditions studied

- Hemophilia A
- Hemophilia B

## Interventions

- **DRUG:** BAY Factor VII (BAY86-6150)
- **DRUG:** BAY Factor VII (BAY86-6150)
- **DRUG:** BAY Factor VII (BAY86-6150)
- **DRUG:** BAY Factor VII (BAY86-6150)
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01921855
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-01
- **Primary completion:** 2009-12
- **Final completion:** 2009-12
- **Target enrollment:** 16 (ACTUAL)
- **Last updated:** 2014-08-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01921855

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01921855, "Study of FVIIa Variant BAY86-6150 (B0189) in Subjects With Moderate or Severe Hemophilia Types A or B With or Without Inhibitors". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT01921855. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*